Book a Meeting

Anti-αVβ3 Integrin Antibody, Non-Fucosylated (BioBet-488ZP) (CAT#: BioBet-488ZP) Datasheet

Target
αVβ3 integrin
Isotype
IgG
Description
Anti-αVβ3 Integrin Antibody, Non-Fucosylated (BioBet-488ZP) is a human monoclonal IgG antibody against αVβ3 integrin. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced αVβ3 integrin antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
αVβ3 Integrin
Alternative Names
etaracizumab/etaratuzumab/MEDI-522;abegrin;892553-42-3;Etaratuzumab;MEDI-522;Abegrin;αVβ3
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BioBet-488ZP
Host
Human
Species Reactivity
Human
Description
ADCC-enhanced etaracizumab/etaratuzumab/MEDI-522 is a non-fucosylated anti-αVβ3 integrin therapeutic biobetter antibody.

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.